Inflammation is a normal part of how the body responds to injury and infection. The problem arises when it becomes chronic and low-grade, quietly contributing to conditions ranging from metabolic disease to accelerated aging. Researchers studying urolithin A (a compound produced when gut bacteria metabolize certain polyphenols found in pomegranate, berries, and walnuts) have identified several biological pathways through which it may help modulate this chronic inflammatory state.
The science here is still developing. Most mechanistic work has been done in cell cultures and animal models, with a smaller number of human trials beginning to fill in the picture. What follows is an honest summary of what the current evidence shows, where it comes from, and what remains uncertain.
Key Takeaways
- Urolithin A appears to modulate inflammation through multiple pathways, including NF-κB suppression and mitophagy-driven removal of damaged mitochondria.
- Most anti-inflammatory findings come from cell culture and animal studies; human clinical trial data directly measuring inflammatory markers is still limited.
- Preclinical research has explored urolithin A’s potential relevance to gut inflammation, cardiovascular disease, bone health, and muscle aging.
- A randomized trial in 88 middle-aged adults missed its primary endpoint (peak power on a cycling test) and reported gains on secondary measures only; the trial was sponsored by the maker of Mitopure [6].
- Urolithin A is not a substitute for proven anti-inflammatory treatments, and none of the research to date supports its use as a therapy for any specific inflammatory disease.
How Urolithin A May Influence Inflammation at the Cellular Level
One of the most studied mechanisms linking urolithin A to inflammation is its ability to promote mitophagy: the cellular process by which damaged or dysfunctional mitochondria are identified and cleared. When mitochondria become damaged, they can release signals that trigger inflammatory cascades. By supporting the timely removal of these damaged organelles, urolithin A may reduce one upstream source of chronic inflammation.
The mitophagy route is not settled. In a mouse liver study, blocking mitophagy did not remove urolithin A’s protection, while silencing Nrf2 did. Cell studies also point to the aryl hydrocarbon receptor, whose role in people taking supplements is not established [12][13].
Beyond mitophagy, urolithin A appears to interact with the NF-κB signaling pathway, a central regulator of inflammatory gene expression. Preclinical work has shown that urolithin A can suppress NF-κB activation and downstream inflammatory signaling, including the pyroptosis pathway: a form of inflammatory cell death [1]. A broad review of the compound’s biological activity also identifies anti-inflammatory effects as a consistent finding across model systems [2].
Urolithin A also has documented antioxidant properties. Oxidative stress and inflammation are tightly coupled: reactive oxygen species can activate inflammatory pathways, and inflammation in turn generates more oxidative damage. Research in animal models has shown that urolithin A’s antioxidative and anti-inflammatory activities operate together in contexts of acute tissue injury [3].
Urolithin A and Gut Inflammation
The gastrointestinal tract is a major site of immune activity, and inflammatory bowel conditions have attracted attention as a potential area where urolithin A could be relevant. A 2024 study explored targeted delivery of urolithin A in models of colitis: both chemically induced and triggered by immune checkpoint inhibitors, a class of cancer therapies known to cause intestinal inflammation as a side effect. The research found that inflammation-targeted delivery of urolithin A helped mitigate colitis in these models [4].
Research note: In mice, urolithin A prevented crystal-induced (gout-type) peritonitis, and in cells it dampened NLRP3 inflammasome activation by reducing reactive oxygen species [14].
It is worth noting that this study used a specialized nanoparticle delivery system to concentrate the compound at sites of gut inflammation, not a standard oral supplement. Whether conventional supplementation achieves comparable local concentrations in human intestinal tissue is not yet established.
Cardiovascular Inflammation and Atherosclerosis
Atherosclerosis, the buildup of plaques inside arterial walls, is fundamentally an inflammatory disease. Immune cells accumulate in arterial walls, foam cells form, and a chronic inflammatory process drives plaque growth and instability. Research in apolipoprotein E-deficient mice, a standard model of atherosclerosis, found that urolithin A promoted plaque stability while limiting both inflammation and hypercholesteremia [5].
These are animal findings and should be interpreted with appropriate caution. Human cardiovascular outcomes research on urolithin A has not yet been conducted at scale. That said, the mechanistic rationale, reducing the inflammatory components that destabilize plaques, is biologically plausible and consistent with urolithin A’s broader anti-inflammatory profile.
Inflammation in Bone and Joint Contexts
Osteoclasts are the cells responsible for breaking down bone tissue. Their overactivation, driven in part by the signaling molecule RANKL and by inflammatory pathways including NF-κB and pyroptosis, contributes to conditions like postmenopausal osteoporosis. Research has shown that urolithin A can suppress RANKL-induced osteoclast formation and inhibit the NF-κB-activated pyroptosis pathways that drive bone loss [1]. This positions inflammation modulation as part of urolithin A’s potential relevance to bone health, not just as a standalone effect.
This research was conducted in cell culture and in a mouse model of postmenopausal bone loss. Human clinical data in this specific application does not yet exist.
Inflammation, Muscle Health, and Exercise
Chronic low-grade inflammation is associated with the gradual loss of muscle mass and function that comes with aging. A randomized clinical trial in middle-aged adults, one of the stronger study designs in the urolithin A literature, missed its pre-specified primary endpoint (peak power on a cycling test); hamstring strength, a secondary endpoint, rose in the treated groups while the placebo group declined, and the peak VO2 comparison with placebo was p = 0.058. The trial was sponsored by the maker of Mitopure [6]. The trial did measure C-reactive protein, an inflammation marker: it was lower at both doses but reached statistical significance only at the 1,000 mg dose. Other small trials were mixed, with no change in CRP in 10 patients with heart failure and a rise within the group in 20 resistance-trained athletes [6][10][11].
Human trials of urolithin A on inflammation markers give mixed results
CRP lower at both doses
Plasma CRP fell at both doses in the middle-aged trial, but the reduction reached statistical significance only at 1,000 mg. The trial was industry-funded.
CRP went up
In a very small trial of 20 resistance-trained male athletes, CRP rose by 0.71 mg/L from baseline within the urolithin A group.
No change in CRP
In 10 patients with heart failure, urolithin A did not change CRP, glucose or pro-BNP.
Dose-dependent effect
A systematic review of five human studies in 250 healthy people reported a dose-dependent anti-inflammatory effect.
Human evidence that urolithin A lowers inflammation is mixed and early.
CRP is a blood marker of inflammation. Results are from separate trials in different populations. Source: Singh et al., Cell Reports Medicine 2022; Zhao et al., Journal of the International Society of Sports Nutrition 2024; Jamialahmadi et al., Reviews on Recent Clinical Trials 2024; Kuerec et al., Ageing Research Reviews 2024.
Chart: urolithinhub.com: Human trials of urolithin A on inflammation markers give mixed results
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
A 2024 systematic review of human trials targeting aging with urolithin A found, across five human studies in 250 healthy people, a dose-dependent anti-inflammatory effect and some upregulated mitochondrial genes, but no effect on maximal mitochondrial ATP production or on physical function [7]. Inflammation was not the primary endpoint in most of these trials, meaning direct human data on urolithin A’s anti-inflammatory effects remains thinner than the preclinical picture.
Urolithin A in Cancer-Related Inflammation Research
Tumor microenvironments are characterized by complex and often pro-tumor inflammatory states. Research has explored whether urolithin A can shift this balance. One study found that urolithin A inhibited breast cancer progression by activating TFEB-mediated mitophagy in tumor-associated macrophages: immune cells that, when dysfunctional, can support tumor growth rather than suppress it [8]. The proposed mechanism involves restoring normal mitophagic function in these macrophages, which may reduce their pro-inflammatory and pro-tumor activity.
This is preclinical research and does not constitute evidence that urolithin A treats or prevents cancer in humans. It does, however, add detail to the mechanistic picture of how urolithin A interacts with inflammation in tissue environments under pathological stress.
Combining Urolithin A with Anti-Inflammatory Drugs
One research direction explores whether urolithin A might be paired with established anti-inflammatory compounds. A 2022 study synthesized conjugates of urolithin A with NSAIDs (non-steroidal anti-inflammatory drugs) and evaluated their stability, cytotoxicity, and anti-inflammatory potential [9]. The rationale is that combining the two might achieve meaningful anti-inflammatory effects at lower doses of each component, potentially reducing side effects.
This work is exploratory and at an early stage. It is not a basis for self-medicating with urolithin A alongside NSAIDs, and anyone taking prescription anti-inflammatories should consult their prescribing physician before adding any supplement.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The majority of urolithin A inflammation research has been conducted in cell cultures and animal models; human clinical trials specifically measuring inflammatory outcomes are limited in number and scale. This article is for informational purposes only and does not constitute medical advice, if you have an inflammatory condition, are taking medications, or are considering supplementation, consult a qualified healthcare provider before making any changes.
Frequently Asked Questions
What is the main mechanism by which urolithin A affects inflammation?
The primary mechanisms appear to involve NF-κB pathway suppression and mitophagy promotion. NF-κB is a master regulator of inflammatory gene expression, and urolithin A has been shown to inhibit its activation along with downstream inflammatory processes including pyroptosis [1]. By also supporting the clearance of damaged mitochondria, which can otherwise trigger inflammatory signals, urolithin A may reduce inflammation at an upstream level [2].
Is there human evidence that urolithin A reduces inflammation?
Human trial data directly measuring inflammatory biomarkers as primary endpoints is limited. A company-funded randomized trial in middle-aged adults missed its primary endpoint and reported gains in muscle strength on secondary measures [6], and a systematic review of five human studies found a dose-dependent anti-inflammatory effect but no effect on physical function [7], but most direct anti-inflammatory data comes from animal and cell-based research.
Could urolithin A help with inflammatory bowel conditions?
Preclinical research using targeted nanoparticle delivery showed that urolithin A helped reduce colitis in animal models, including inflammation triggered by immune checkpoint inhibitor cancer therapies [4]. However, this used a specialized delivery system, not standard oral supplementation, and no human clinical trials in inflammatory bowel disease have been published to date.
Does urolithin A have anti-inflammatory effects on the heart and blood vessels?
Animal research in a standard atherosclerosis model found that urolithin A promoted plaque stability and reduced both vascular inflammation and hypercholesteremia [5]. These are promising preclinical findings, but human cardiovascular evidence is minimal: a small crossover trial in 10 patients with heart failure found no significant change in heart function, and its authors said the results do not support a benefit [10].
Can everyone produce urolithin A from diet alone?
No. Urolithin A is produced when gut bacteria convert ellagitannins (found in pomegranate, walnuts, and berries) into urolithin A. Research has shown that only a portion of people have the gut microbiome composition necessary to produce meaningful amounts, and production varies significantly between individuals. This variability is one reason researchers have studied supplemental urolithin A as a way to ensure consistent exposure.
Are there any safety concerns with urolithin A supplementation?
Available human studies have not raised significant safety concerns at the doses tested. However, research in humans is still at an early stage, long-term safety data is limited, and interactions with medications, particularly anti-inflammatory drugs or immunosuppressants, have not been thoroughly studied in clinical settings [7]. Anyone with a chronic health condition or on prescription medication should consult a physician before supplementing.
References
- Tao H et al. Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways. Pharmacological research (2021). PMID 34740817
- D'Amico D et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends in molecular medicine (2021). PMID 34030963
- Karim S et al. Urolithin A's Antioxidative, Anti-Inflammatory, and Antiapoptotic Activities Mitigate Doxorubicin-Induced Liver Injury in Wistar Rats. Biomedicines (2023). PMID 37189743
- Ghosh S et al. Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis. Journal of nanobiotechnology (2024). PMID 39533380
- Xu MY et al. Urolithin A promotes atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in Apolipoprotein E-deficient mice. Acta pharmacologica Sinica (2024). PMID 38886550
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Zheng B et al. Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages. Journal of advanced research (2025). PMID 38615740
- Korczak M et al. Conjugates of urolithin A with NSAIDs, their stability, cytotoxicity, and anti-inflammatory potential. Scientific reports (2022). PMID 35804000
- Jamialahmadi T et al. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial. Reviews on recent clinical trials (2024). PMID 38415449
- Zhao H et al. Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. Journal of the International Society of Sports Nutrition (2024). PMID 39487653
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Devries MC et al. Creatine supplementation during resistance training in older adults-a meta-analysis. Medicine and science in sports and exercise (2014). PMID 24576864
- Komatsu W et al. Urolithin A suppresses NLRP3 inflammasome activation by inhibiting the generation of reactive oxygen species and prevents monosodium urate crystal-induced peritonitis. Bioscience, biotechnology, and biochemistry (2024). PMID 38772744
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.